Stockscreener 앱 받기
1.79
2.87%
0.05
시간 외 거래:
1.79
전일 마감가:
$1.74
열려 있는:
$1.74
하루 거래량:
959.15K
Relative Volume:
0.82
시가총액:
$128.21M
수익:
순이익/손실:
$-104.08M
주가수익비율:
-1.2723
EPS:
-1.4069
순현금흐름:
$-89.91M
1주 성능:
-0.56%
1개월 성능:
-35.14%
6개월 성능:
-39.93%
1년 성능:
-20.80%
1일 변동 폭
$1.66
$1.81
1주일 범위
$1.66
$1.85
52주 변동 폭
$1.66
$3.72
엔카르타 Stock (NKTX) Company Profile
명칭
Nkarta Inc
전화
(925) 407-1049
주소
1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO
Compare NKTX vs VRTX, REGN, MRNA, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NKTX
Nkarta Inc
|
1.79 | 128.21M | 0 | -104.08M | -89.91M | -1.4069 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
엔카르타 Stock (NKTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-06-23 | 개시 | TD Cowen | Buy |
| 2025-05-15 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-10-09 | 개시 | Rodman & Renshaw | Buy |
| 2024-08-14 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-03-22 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2022-12-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-10-10 | 개시 | Canaccord Genuity | Buy |
| 2022-07-28 | 개시 | Needham | Buy |
| 2022-07-18 | 개시 | SVB Leerink | Outperform |
| 2022-03-11 | 개시 | Raymond James | Outperform |
| 2022-03-08 | 개시 | H.C. Wainwright | Buy |
| 2022-01-06 | 개시 | William Blair | Outperform |
| 2021-11-18 | 개시 | SMBC Nikko | Outperform |
| 2021-07-16 | 개시 | Oppenheimer | Outperform |
| 2020-08-04 | 개시 | Cowen | Outperform |
| 2020-08-04 | 개시 | Evercore ISI | Outperform |
| 2020-08-04 | 개시 | Mizuho | Buy |
| 2020-08-04 | 개시 | Stifel | Buy |
모두보기
엔카르타 주식(NKTX)의 최신 뉴스
Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease - The Manila Times
Nkarta (NKTX) Edges Higher to $2.58 as Traders Watch $2.45 Support and $2.71 ResistanceATR Trailing Stop - siam.in
Lantern Pharma Inc. (LTRN) stock price, news, quote and history - Yahoo Finance Australia
Lantern Pharma Inc. (LTRN) stock price, news, quote and history - Yahoo Finance UK
Stifel reiterates Buy rating on Nkarta stock, cites trial progress By Investing.com - Investing.com Nigeria
Stifel reiterates Buy rating on Nkarta stock, cites trial progress - Investing.com
Stifel reiterates Buy rating on Nkarta stock, cites trial progress By Investing.com - Investing.com UK
Nkarta to Participate in September Investor Conferences - Investing News Network
Two Nkarta investor talks will be webcast in September - Stock Titan
Nkarta Insiders Got A Good Deal Selling At US$2.10 - simplywall.st
Nkarta to Present Initial Autoimmune Clinical Data for - GlobeNewswire
Nkarta’s autoimmune cell therapy will get two talks and a poster - Stock Titan
Nkarta: 'Hold' NKX019 Discontinuation For R/R NHL And Pivot To Autoimmune Disorders - Seeking Alpha
NKARTA STOCK : BIG PRICE RECOVERY | NKTX STOCK Rinku Singh (yKkQAHM32g) - Mshale
Nkarta Inc (NASDAQ: NKTX) Stock Price, News & Analysis - Kalkine
Dare Bioscience Prices $6.0 Million Registered Direct Offering - minichart.com.sg
Monaco Asset Management SAM Makes New Investment in Nkarta, Inc. $NKTX - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Idexx Laboratories (IDXX), Nkarta (NKTX) - The Globe and Mail
Nkarta (NASDAQ:NKTX) Stock Rating Lowered by Wall Street Zen - MarketBeat
Stifel cuts Nkarta stock price target on updated model By Investing.com - Investing.com Australia
Stifel cuts Nkarta stock price target on updated model By Investing.com - Investing.com Canada
Stifel cuts Nkarta stock price target on updated model By Investing.com - Investing.com Nigeria
Stifel cuts Nkarta stock price target on updated model - Investing.com
Stifel cuts Nkarta stock price target on updated model By Investing.com - Investing.com India
Stifel cuts Nkarta stock price target on updated model By Investing.com - Investing.com UK
Stifel cuts Nkarta stock price target on updated model - Investing.com
Stifel Nicolaus Has Lowered Expectations for Nkarta (NASDAQ:NKTX) Stock Price - MarketBeat
Nkarta Inc (NASDAQ: NKTX) Stock Price, News & Analysis - kalkine.ca
Nkarta Inc. (NKTX) Edges Higher as Biotech Stock Holds Key Support ZoneEase of Movement - vinanet.vn
Nkarta Inc. (NKTX) Edges Higher as Biotech Stock Holds Key Support ZoneHigh Conviction Picks - dars.gov.et
Equities Analysts Set Expectations for Nkarta Q3 Earnings - MarketBeat
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX) and Rocket Pharmaceuticals (RCKT) - The Globe and Mail
NKARTA STOCK : BIG PRICE RECOVERY | NKTX STOCK Rinku Singh (yKkQAHM32g) - Mshale
Nkarta, Inc. Stock 12‑Month Price Target Cut to $11, Implies 347% Upside - TradingView
H.C. Wainwright cuts Nkarta stock price target on trial progress - Investing.com
H.C. Wainwright cuts Nkarta stock price target on trial progress By Investing.com - Investing.com Australia
H.C. Wainwright cuts Nkarta stock price target on trial progress By Investing.com - Investing.com UK
H.C. Wainwright cuts Nkarta stock price target on trial progress - Investing.com
NKARTA, INC. : H.C. WAINWRIGHT CUTS TARGET PRICE TO $14 FROM $16 - Bitget
NKTX Q2 2026 Earnings: Wider Loss of $0.54 Per Share Misses Estimates as Clinical-Stage Costs EscalateFinancial Data - vinanet.vn
Nkarta, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Nkarta (NASDAQ:NKTX) Posts Quarterly Earnings Results, Misses Estimates By $0.18 EPS - MarketBeat
Nkarta Q2 EPS of $(0.54) misses $(0.38) analyst estimate - scanx.trade
Nkarta Reports Continued Enrollment in Ntrust Autoimmune Trials and $243.2 Million Cash Position, Reaffirms Runway Into 2029 - Quiver Quantitative
Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights - GlobeNewswire
Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights - Yahoo Finance
Nkarta, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
NKTX Q1 2026 Earnings: Narrower-Than-Expected Loss Supports 5.24% Share GainROIC Trend Report - vinanet.vn
Nkarta, Inc. expected to post a loss of 38 cents a shareEarnings Preview - TradingView
엔카르타 (NKTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
엔카르타 주식 (NKTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| HASTINGS PAUL J | Chief Executive Officer |
Jan 15 '26 |
Sale |
2.07 |
26,046 |
53,915 |
390,023 |
| Mahmood Nadir | President |
Jan 15 '26 |
Sale |
2.07 |
5,649 |
11,693 |
167,727 |
3.09%
0.72%
자본화:
|
볼륨(24시간):